Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3011 and PD-1/PD-L1 Inhibitors in Advanced Solid Tumors
NCT06214143Phase 2Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MVR-T3011 in solid tumor (advanced stage), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 2 years and Objective Response Rate at 2 years. Started Jan 2024; status: recruiting.
02
Drugs
MVR-T3011
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06214143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06214143.